Drugs for the treatment of respiratory diseases
Author(s)
Bibliographic Information
Drugs for the treatment of respiratory diseases
Cambridge University Press, c2003
Available at 3 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Includes bibliographical references and index
Description and Table of Contents
Description
Respiratory diseases affect millions of people each year and represent a major health burden around the world. This timely reference surveys and evaluates the drug treatments available for the main categories of lung diseases including asthma, tuberculosis, chronic obstructive pulmonary disease, lung cancer, and respiratory infections. The recent re-emergence of tuberculosis and the increase in asthma in certain populations underlines the importance of finding effective new treatments for these diseases. This publication, a comprehensive reference, is one of the first to survey current and novel drug treatments for this group of diseases. It is certain to establish itself as an essential source of reference for respiratory physicians, clinicians and clinical pharmacologists.
Table of Contents
- Part I. Asthma and COPD: 1. Pathology of asthma and COPD Peter K. Jeffery
- 2. Glucocorticosteroids Peter J. Barnes
- 3. ss2- adrenoceptor agonists Domenico Spina, Clive P. Page and Brian J. O'Connor
- 4. Anticholinergic bronchodilators Jeremy M. Segal and Nicholas J. Gross
- 5. Antiallergic drugs Mazakazu Ichinose
- 6. Drugs affecting the synthesis and action of leukotrienes Paul M. O'Byrne
- 7. Theophylline and selective phosphodiesterase inhibitors in the treatment of respiratory disease N. A. Jones, Domenico Spina and Clive P. Page
- 8. Potential therapeutic effects of potassium channel openers in respiratory diseases Ahmed Z. El-Hashim
- 9. Tachykinin and kinin antagonists Pierangelo Geppetti
- 10. Drugs affecting IgE (synthesis inhibitors and monoclonal antibodies) Lawrence G. Garland and Alan G. Lamont
- 11. Drugs targeting cell signalling Brydon L. Bennett, Yoshitaka Satoh and Alan J. Lewis
- Part II. Diffuse Parenchymal Lung Disease: 12. Current approaches to the treatment of parenchymal lung diseases Joseph P. Lynch III and Michael Keane
- 13. Drug treatments of the future in fibrotic lung disease Athol U. Wells
- Part III. Infection: 14. Current and future management of pneumonia Mario Cazzola and Maria G. Matera
- 15. Current treatment of chronic bronchial suppuration Robert Wilson
- 16. Current and future treatment of cystic fibrosis R. Gary, G. Ruiz, Hilary Wyatt and John F. Price
- Part IV. Pulmonary Vascular Diseases: 17. Pathophysiology of pulmonary vascular disease Sanjay Mehta and David G. McCormack
- 18. Current treatment of pulmonary vascular diseases Tarek Saba and Andrew Peacock
- 19. Future treatment of pulmonary vascular diseases Norbert F. Voelkel, M. W. Geraci and S. Abman
- Part V. Lung Cancer:20. Molecular pathology of lung cancer Ignacio I. Wistuba and Adi F. Gazdar
- 21. Small cell lung cancer Desmond N. Carney
- Part VI. Cough: 22. Mechanisms of cough John J. Adcock
- 23. Current treatment of cough Peter V. Dicpinigaitis.
by "Nielsen BookData"